These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 15161783

  • 1. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.
    Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR, Ragaglitazar Dose-Ranging Study Group.
    Diabetes Care; 2004 Jun; 27(6):1324-9. PubMed ID: 15161783
    [Abstract] [Full Text] [Related]

  • 2. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 3. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [Abstract] [Full Text] [Related]

  • 4. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
    Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B.
    J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179
    [Abstract] [Full Text] [Related]

  • 5. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [Abstract] [Full Text] [Related]

  • 6. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
    Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldórsdóttir S, Gause-Nilsson I.
    Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
    [Abstract] [Full Text] [Related]

  • 7. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [Abstract] [Full Text] [Related]

  • 8. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, Faldu K, Maroo S, PRESS XII study group, Parmar D.
    Cardiovasc Diabetol; 2020 Jun 19; 19(1):93. PubMed ID: 32560724
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May 19; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 10. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
    Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.
    Clin Ther; 2005 Aug 19; 27(8):1181-95. PubMed ID: 16199244
    [Abstract] [Full Text] [Related]

  • 11. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators.
    Diabetes Care; 2005 Jul 19; 28(7):1547-54. PubMed ID: 15983299
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
    Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R.
    Br J Pharmacol; 2003 Oct 19; 140(3):527-37. PubMed ID: 12970088
    [Abstract] [Full Text] [Related]

  • 15. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.
    Metabolism; 2007 Sep 19; 56(9):1285-92. PubMed ID: 17697874
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P, Quartet [corrected] Study Group.
    J Clin Endocrinol Metab; 2004 Dec 19; 89(12):6068-76. PubMed ID: 15579760
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator.
    Mamnoor PK, Hegde P, Datla SR, Damarla RK, Rajagopalan R, Chakrabarti R.
    Pharmacol Res; 2006 Aug 19; 54(2):129-35. PubMed ID: 16651004
    [Abstract] [Full Text] [Related]

  • 18. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
    Avogaro A, Piliego T, Catapano A, Miola M, Tiengo A.
    Acta Diabetol; 1999 Jun 19; 36(1-2):27-33. PubMed ID: 10436249
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov 19; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 20. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
    Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA.
    Drugs R D; 2006 Nov 19; 7(2):99-110. PubMed ID: 16542056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.